Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A. Koutsilieris M, et al. Among authors: sourla a. BJU Int. 2007 Jul;100 Suppl 2:60-2. doi: 10.1111/j.1464-410X.2007.06958.x. BJU Int. 2007. PMID: 17594363 Review. No abstract available.
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A. Koutsilieris M, et al. Among authors: sourla a. Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. doi: 10.1517/13543784.15.7.795. Expert Opin Investig Drugs. 2006. PMID: 16787142 Review.
Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Mitsiades CS, et al. Among authors: sourla a. Clin Exp Metastasis. 2004;21(6):495-505. doi: 10.1007/s10585-004-3217-0. Clin Exp Metastasis. 2004. PMID: 15679047
Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).
Karamanolakis D, Lambou T, Bogdanos J, Milathianakis C, Sourla A, Lembessis P, Halapas A, Pissimissis N, Dessypris N, Petridou ET, Koutsilieris M. Karamanolakis D, et al. Among authors: sourla a. Anticancer Res. 2006 Jul-Aug;26(4B):3159-66. Anticancer Res. 2006. PMID: 16886650 Free article.
Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M. Lembessis P, et al. Among authors: sourla a. Clin Chem Lab Med. 2007;45(11):1488-94. doi: 10.1515/CCLM.2007.301. Clin Chem Lab Med. 2007. PMID: 17924845
Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.
Sourla A, Lembessis P, Mitsiades C, Dimopoulos T, Skouteris M, Metsinis M, Ntounis A, Ioannidis A, Katsoulis A, Kyragiannis V, Lambou T, Tsintavis A, Koutsilieris M. Sourla A, et al. Anticancer Res. 2001 Sep-Oct;21(5):3565-70. Anticancer Res. 2001. PMID: 11848524
55 results